英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - vardenafil hydrochloride trihydrate - oral tablet - 20mg

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - vardenafil hydrochloride trihydrate - orodispersible tablet - 10 milligram(s) - drugs used in erectile dysfunction; vardenafil

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sovereign medical ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

aristo pharma ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

rivopharm (uk) ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg

美国 - 英文 - NLM (National Library of Medicine)

lannett company, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride tablets with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil hydrochloride tablets for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil hydrochloride tablets are not indicated for use in females. there

美国 - 英文 - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil is not indicated for use in females. there are no data with the use of vardenafil in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits, no adverse deve